Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Approximately 30–40% of patients with acute myeloid leukemia (AML) experience induction failures. In these patients who do not achieve remission with two cycles of standard induction therapies, the probability of achieving remission with subsequent inductions is very limited. Hematopoietic stem cell transplantation (HSCT) is the only curative option for these patients, but high relapse rate and transplant-related mortality often preclude them to proceed to transplant. Thus, AML not in remission at time of HSCT remains a huge unmet need in current HSCT practice, particularly if the patient does not have an HLA-matched donor identified by the time of two induction failures. We used clofarabine cytoreduction immediately followed by fludarabine (Flu) and busulfan (Bu) × 3 with total-body irradiation (TBI) conditioning (Flu/Bu3/TBI) for haploidentical peripheral blood stem cell transplant with post-transplant cyclophosphamide for two cases of refractory AML with a very high tumor burden at transplant and achieved complete remission by day + 30 in both cases.

Original languageEnglish (US)
Pages (from-to)348-350
Number of pages3
JournalInternational journal of hematology
Volume108
Issue number3
DOIs
StatePublished - Sep 1 2018

Fingerprint

Busulfan
Whole-Body Irradiation
Acute Myeloid Leukemia
Cyclophosphamide
Stem Cells
Hematopoietic Stem Cell Transplantation
Transplants
Tumor Burden
clofarabine
fludarabine
Tissue Donors
Recurrence
Mortality

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

@article{ad5bf1c4885c4afb9f891f5f6e85f4a8,
title = "Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML",
abstract = "Approximately 30–40{\%} of patients with acute myeloid leukemia (AML) experience induction failures. In these patients who do not achieve remission with two cycles of standard induction therapies, the probability of achieving remission with subsequent inductions is very limited. Hematopoietic stem cell transplantation (HSCT) is the only curative option for these patients, but high relapse rate and transplant-related mortality often preclude them to proceed to transplant. Thus, AML not in remission at time of HSCT remains a huge unmet need in current HSCT practice, particularly if the patient does not have an HLA-matched donor identified by the time of two induction failures. We used clofarabine cytoreduction immediately followed by fludarabine (Flu) and busulfan (Bu) × 3 with total-body irradiation (TBI) conditioning (Flu/Bu3/TBI) for haploidentical peripheral blood stem cell transplant with post-transplant cyclophosphamide for two cases of refractory AML with a very high tumor burden at transplant and achieved complete remission by day + 30 in both cases.",
author = "Rakszawski, {Kevin L.} and Kosuke Miki and David Claxton and Henry Wagner and Hiroko Shike and Shin Mineishi and Seema Naik",
year = "2018",
month = "9",
day = "1",
doi = "10.1007/s12185-018-2431-5",
language = "English (US)",
volume = "108",
pages = "348--350",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML

AU - Rakszawski, Kevin L.

AU - Miki, Kosuke

AU - Claxton, David

AU - Wagner, Henry

AU - Shike, Hiroko

AU - Mineishi, Shin

AU - Naik, Seema

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Approximately 30–40% of patients with acute myeloid leukemia (AML) experience induction failures. In these patients who do not achieve remission with two cycles of standard induction therapies, the probability of achieving remission with subsequent inductions is very limited. Hematopoietic stem cell transplantation (HSCT) is the only curative option for these patients, but high relapse rate and transplant-related mortality often preclude them to proceed to transplant. Thus, AML not in remission at time of HSCT remains a huge unmet need in current HSCT practice, particularly if the patient does not have an HLA-matched donor identified by the time of two induction failures. We used clofarabine cytoreduction immediately followed by fludarabine (Flu) and busulfan (Bu) × 3 with total-body irradiation (TBI) conditioning (Flu/Bu3/TBI) for haploidentical peripheral blood stem cell transplant with post-transplant cyclophosphamide for two cases of refractory AML with a very high tumor burden at transplant and achieved complete remission by day + 30 in both cases.

AB - Approximately 30–40% of patients with acute myeloid leukemia (AML) experience induction failures. In these patients who do not achieve remission with two cycles of standard induction therapies, the probability of achieving remission with subsequent inductions is very limited. Hematopoietic stem cell transplantation (HSCT) is the only curative option for these patients, but high relapse rate and transplant-related mortality often preclude them to proceed to transplant. Thus, AML not in remission at time of HSCT remains a huge unmet need in current HSCT practice, particularly if the patient does not have an HLA-matched donor identified by the time of two induction failures. We used clofarabine cytoreduction immediately followed by fludarabine (Flu) and busulfan (Bu) × 3 with total-body irradiation (TBI) conditioning (Flu/Bu3/TBI) for haploidentical peripheral blood stem cell transplant with post-transplant cyclophosphamide for two cases of refractory AML with a very high tumor burden at transplant and achieved complete remission by day + 30 in both cases.

UR - http://www.scopus.com/inward/record.url?scp=85043707334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043707334&partnerID=8YFLogxK

U2 - 10.1007/s12185-018-2431-5

DO - 10.1007/s12185-018-2431-5

M3 - Article

C2 - 29542029

AN - SCOPUS:85043707334

VL - 108

SP - 348

EP - 350

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -